An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

What is the purpose of this trial?

The purpose of this study is to explore the possible links between patient characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in patients with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).

Participation Guidelines

Ages: 18 years and older

Gender: Both

Bristol-Myers Squibb Research and Development

Start Date: 04/20/2017

End Date: 01/01/2021

Last Updated: 02/21/2019

Study HIC#: 2000020087